BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 26598975)

  • 1. A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
    Eram MS; Shen Y; Szewczyk M; Wu H; Senisterra G; Li F; Butler KV; Kaniskan HÜ; Speed BA; Dela Seña C; Dong A; Zeng H; Schapira M; Brown PJ; Arrowsmith CH; Barsyte-Lovejoy D; Liu J; Vedadi M; Jin J
    ACS Chem Biol; 2016 Mar; 11(3):772-781. PubMed ID: 26598975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
    Fong JY; Pignata L; Goy PA; Kawabata KC; Lee SC; Koh CM; Musiani D; Massignani E; Kotini AG; Penson A; Wun CM; Shen Y; Schwarz M; Low DH; Rialdi A; Ki M; Wollmann H; Mzoughi S; Gay F; Thompson C; Hart T; Barbash O; Luciani GM; Szewczyk MM; Wouters BJ; Delwel R; Papapetrou EP; Barsyte-Lovejoy D; Arrowsmith CH; Minden MD; Jin J; Melnick A; Bonaldi T; Abdel-Wahab O; Guccione E
    Cancer Cell; 2019 Aug; 36(2):194-209.e9. PubMed ID: 31408619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6.
    Shen Y; Szewczyk MM; Eram MS; Smil D; Kaniskan HÜ; de Freitas RF; Senisterra G; Li F; Schapira M; Brown PJ; Arrowsmith CH; Barsyte-Lovejoy D; Liu J; Vedadi M; Jin J
    J Med Chem; 2016 Oct; 59(19):9124-9139. PubMed ID: 27584694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation.
    Wang C; Jiang H; Jin J; Xie Y; Chen Z; Zhang H; Lian F; Liu YC; Zhang C; Ding H; Chen S; Zhang N; Zhang Y; Jiang H; Chen K; Ye F; Yao Z; Luo C
    J Med Chem; 2017 Nov; 60(21):8888-8905. PubMed ID: 29019697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor.
    Shen Y; Li F; Szewczyk MM; Halabelian L; Park KS; Chau I; Dong A; Zeng H; Chen H; Meng F; Barsyte-Lovejoy D; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
    J Med Chem; 2020 May; 63(10):5477-5487. PubMed ID: 32367723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I and II PRMTs inversely regulate post-transcriptional intron detention through Sm and CHTOP methylation.
    Maron MI; Casill AD; Gupta V; Roth JS; Sidoli S; Query CC; Gamble MJ; Shechter D
    Elife; 2022 Jan; 11():. PubMed ID: 34984976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A patent review of arginine methyltransferase inhibitors (2010-2018).
    Li X; Wang C; Jiang H; Luo C
    Expert Opin Ther Pat; 2019 Feb; 29(2):97-114. PubMed ID: 30640571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
    Dominici C; Sgarioto N; Yu Z; Sesma-Sanz L; Masson JY; Richard S; Raynal NJ
    Clin Epigenetics; 2021 Mar; 13(1):54. PubMed ID: 33691794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
    Fedoriw A; Rajapurkar SR; O'Brien S; Gerhart SV; Mitchell LH; Adams ND; Rioux N; Lingaraj T; Ribich SA; Pappalardi MB; Shah N; Laraio J; Liu Y; Butticello M; Carpenter CL; Creasy C; Korenchuk S; McCabe MT; McHugh CF; Nagarajan R; Wagner C; Zappacosta F; Annan R; Concha NO; Thomas RA; Hart TK; Smith JJ; Copeland RA; Moyer MP; Campbell J; Stickland K; Mills J; Jacques-O'Hagan S; Allain C; Johnston D; Raimondi A; Porter Scott M; Waters N; Swinger K; Boriack-Sjodin A; Riera T; Shapiro G; Chesworth R; Prinjha RK; Kruger RG; Barbash O; Mohammad HP
    Cancer Cell; 2019 Jul; 36(1):100-114.e25. PubMed ID: 31257072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical probes for protein arginine methyltransferases.
    Li ASM; Li F; Eram MS; Bolotokova A; Dela Seña CC; Vedadi M
    Methods; 2020 Mar; 175():30-43. PubMed ID: 31809836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6.
    Shen Y; Li F; Szewczyk MM; Halabelian L; Chau I; Eram MS; Dela Seña C; Park KS; Meng F; Chen H; Zeng H; Dong A; Wu H; Trush VV; McLeod D; Zepeda-Velázquez CA; Campbell RM; Mader MM; Watson BM; Schapira M; Arrowsmith CH; Al-Awar R; Barsyte-Lovejoy D; Kaniskan HÜ; Brown PJ; Vedadi M; Jin J
    J Med Chem; 2021 Apr; 64(7):3697-3706. PubMed ID: 33591753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic mechanism of protein arginine methyltransferase 6 (PRMT6).
    Obianyo O; Thompson PR
    J Biol Chem; 2012 Feb; 287(8):6062-71. PubMed ID: 22219200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone H4K20 monomethylation enables recombinant nucleosome methylation by PRMT1 in vitro.
    Li ASM; Homsi C; Bonneil E; Thibault P; Verreault A; Vedadi M
    Biochim Biophys Acta Gene Regul Mech; 2023 Jun; 1866(2):194922. PubMed ID: 36822575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic mechanism of protein arginine methyltransferase 1.
    Obianyo O; Osborne TC; Thompson PR
    Biochemistry; 2008 Sep; 47(39):10420-7. PubMed ID: 18771293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance.
    Zhu Y; Xia T; Chen DQ; Xiong X; Shi L; Zuo Y; Xiao H; Liu L
    Drug Resist Updat; 2024 Jan; 72():101016. PubMed ID: 37980859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecule Inhibitors of Protein Arginine Methyltransferases.
    Hu H; Qian K; Ho MC; Zheng YG
    Expert Opin Investig Drugs; 2016; 25(3):335-58. PubMed ID: 26789238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer.
    Shailesh H; Zakaria ZZ; Baiocchi R; Sif S
    Oncotarget; 2018 Nov; 9(94):36705-36718. PubMed ID: 30613353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein arginine methyltransferases and cancer.
    Yang Y; Bedford MT
    Nat Rev Cancer; 2013 Jan; 13(1):37-50. PubMed ID: 23235912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent transcriptomic and proteomic regulation by type I and II protein arginine methyltransferases.
    Maron MI; Lehman SM; Gayatri S; DeAngelo JD; Hegde S; Lorton BM; Sun Y; Bai DL; Sidoli S; Gupta V; Marunde MR; Bone JR; Sun ZW; Bedford MT; Shabanowitz J; Chen H; Hunt DF; Shechter D
    iScience; 2021 Sep; 24(9):102971. PubMed ID: 34505004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The C. elegans PRMT-3 possesses a type III protein arginine methyltransferase activity.
    Takahashi Y; Daitoku H; Yokoyama A; Nakayama K; Kim JD; Fukamizu A
    J Recept Signal Transduct Res; 2011 Apr; 31(2):168-72. PubMed ID: 21385054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.